The startup develops non-invasive immunodiagnostic kits utilizing a multiplex biomarkers panel with high sensitivity and specificity for bladder cancer diagnosis and monitoring. This technology provides researchers with accurate and conclusive testing results, enhancing the reliability of bladder cancer assessments.

The startup is developing chimeric antigen receptor (CAR) T-cell therapies specifically targeting solid tumors and lymphoproliferative diseases. This approach addresses the need for effective treatments in complex cancer cases, enabling patients to receive tailored therapies that improve their quality of life.

BluMaiden uses AI‑driven computational chemistry to convert metagenomic and multi‑omics data into predicted structures of human‑derived natural products, uncovering the hidden “chemical dark matter” of bioactive compounds. Its platform integrates genome‑to‑molecule translation, scaffold prediction, and ligand‑target interaction modeling to prioritize and optimize evolutionarily refined drug candidates for pharmaceutical and biotech development.

BrainXell specializes in producing high-purity, iPSC-derived human neurons, astrocytes, and microglia for research and drug discovery in central nervous system disorders. The company provides customizable cell lines in various quantities, enabling researchers to advance their studies with precise, patient-derived cellular models.

SCG Cell Therapy utilizes the patient's immune system to target and eliminate cancerous cells and pathogenic infections. This approach aims to enhance the effectiveness of cancer treatment by harnessing the body's natural defenses.